Has lorlatinib been officially launched in China?

Lorlatinib (Lolatinib) is a third-generation ALK (anaplastic lymphoma kinase) /ROS1 targeted inhibitor, mainly used to treat ALKpositive or ROS1positive non-small cell lung cancer (NSCLC) play an important role especially in the regimen after failure of previous generation ALK inhibitor treatment. At present, lorlatinib has been officially approved for marketing in mainland China and has been included in the National Reimbursement Directory, indicating that the drug has a legal and compliant basis for clinical use and a patient reimbursement path.

In terms of domestic sales, lorlatinib is usually supplied by Pfizer (Pfizer) under the trade name "Leviza" in the specification of 100mg tablets. Depending on the reimbursement ratio of regional hospitals and medical insurance, the patient's out-of-pocket price is about 10,000 to 20,000 yuan. It should be noted that the medical insurance reimbursement policies of different provinces and cities are slightly different. For specific personal responsibilities, it is recommended to consult the pharmacy department of the hospital or the medical insurance window to obtain accurate cost calculation and reimbursement process guidance.

At the same time, the original drug and generic drugs of lorlatinib are also available in other parts of the world. The original version in the Turkish market has better channel price control, with a price of more than 7,000 yuan, and has attracted the attention of some cross-border patients. The price of the original version in Hong Kong is on the higher side, reaching more than 30,000 yuan. In addition, the price of generic versions in Laos, Bangladesh and other places is more affordable, about more than 1,000 yuan per box, and usually uses the same ingredients and dosage standards. However, since it has not been officially registered and marketed in China, it is necessary to carefully evaluate the channels and drug quality before use.

Overall, the official launch of lorlatinib in China and its inclusion in medical insurance have greatly improved its accessibility and standardized treatment basis for local patients. Although the price is still relatively high, the intervention of medical insurance policies has eased the burden on some patients. For patients with limited financial conditions or insufficient medical insurance coverage, they can also learn about regular overseas generic drug channels based on actual conditions, but priority must be given to ensuring drug safety and source compliance to avoid unknown private purchase channels that may affect the treatment effect.

Reference materials:https://www.drugs.com/